Laquinimod: Phase III data

Top-line data from the double-blind, international Phase III ALLEGRO trial in 1,106 patients showed that once-daily 0.6 mg oral laquinimod met the primary endpoint of significantly reducing ARR from baseline to 2 years vs. placebo. Laquinimod also met the secondary endpoint of significantly reducing disability progression as measured by EDSS scores vs. placebo. Laquinimod was well tolerated, and the overall incidence of adverse events and infections were similar between treatment groups. There were no deaths in laquinimod-treated patients. Patients who completed the trial have the option to enroll in an open-label extension phase. ...